

BIO  
CONF

(SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-28 (SEQ ID NO: 53), CJ1-29 (SEQ ID NO: 54), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), CJ1-33 (SEQ ID NO: 58), CJ1-34 (SEQ ID NO: 59) and CJ1-35 (SEQ ID NO: 60)--;

In the Claims

Please amend claims 1, 18-19, 25-27, 32, 51-52 and 74 as follows:

21

1. (Amended) An isolated peptide of Cry j I or an isolated portion thereof comprising at least one T cell epitope of Cry j I, said peptide having an amino acid sequence selected from the group consisting of CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), and CJ1-35 (SEQ ID NO: 60).

18. (Amended) A peptide or portion thereof of claim 14 wherein said peptide is selected from the group consisting of: CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-35 (SEQ ID NO: 60).

19. (Amended) A peptide or portion thereof of claim 17 wherein said peptide has an amino acid sequence selected from the group consisting of: CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47), CJ1-27 (SEQ ID NO: 52) and CJ1-32 (SEQ ID NO: 57).

25. (Amended) An isolated peptide comprising at least two regions, each region comprising at least one T cell epitope of Cry j I, said regions each comprising all or a portion of an amino acid sequence selected from the group consisting of: CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17

(SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-28 (SEQ ID NO: 53), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), CJ1-33 (SEQ ID NO: 58), CJ1-34 (SEQ ID NO: 59) and CJ1-35 (SEQ ID NO: 60).

26. (Amended) All or a portion of an isolated peptide of claim 25 wherein said regions comprise an amino acid sequence selected from the group consisting of: CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-35 (SEQ ID NO: 60).

27. (Amended) An isolated peptide of claim 25, wherein said peptide comprises a combination of regions selected from the group consisting of:

CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-1 (SEQ ID NO: 26) and CJ1-2 (SEQ ID NO: 27);

CJ1-9 (SEQ ID NO: 34) and CJ1-10 (SEQ ID NO: 35);

213  
CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16  
(SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);  
CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22  
(SEQ ID NO: 47), CJ2-23 (SEQ ID NO: 48);  
CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47) and CJ1-23  
(SEQ ID NO: 48);  
CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);  
CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48) and CJ1-24  
(SEQ ID NO: 49);  
CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56) and CJ1-32  
(SEQ ID NO: 57);  
CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);  
CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-16  
(SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);  
CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31  
(SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);  
CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31  
(SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);  
CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35) and CJ1-16  
(SEQ ID NO: 41);  
CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23  
(SEQ ID NO: 48);  
CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42) and CJ1-20  
(SEQ ID NO: 45);

CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-20 (SEQ ID NO: 45);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57); and

CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48).

24  
32. (Amended) All or a portion of an isolated peptide of Cry j I, said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide having the formula  $X_n$ -Y- $Z_m$ , wherein Y is an amino acid sequence selected from the group consisting of: CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), and CJ1-35 (SEQ ID NO: 60) wherein  $X_n$  are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of said protein allergen, wherein  $Z_m$  are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of said protein allergen, wherein n is 0-30 and wherein m is 0-30.

815

51. (Amended) A composition of claim 50 wherein said peptides are selected from the group consisting of: CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-28 (SEQ ID NO: 53), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), CJ1-33 (SEQ ID NO: 58), CJ1-34 (SEQ ID NO: 59) and CJ1-35 (SEQ ID NO: 60) and wherein said composition comprises a sufficient percentage of the T cell epitopes of said protein allergen such that upon administration of the composition to an individual sensitive to a Japanese cedar pollen allergen, T cells of the individual are tolerized to said at least one protein allergen.

52. (Amended) A composition of claim 51 comprising a combination of peptides selected from the group consisting of:

CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-1 (SEQ ID NO: 26) and CJ1-2 (SEQ ID NO: 27);

CJ1-9 (SEQ ID NO: 34) and CJ1-10 (SEQ ID NO: 35);

CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);

CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ2-23 (SEQ ID NO: 48);

CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48) and CJ1-24 (SEQ ID NO: 49);

CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-16 (SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

7/5  
CJ1-23



CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35) and CJ1-16  
(SEQ ID NO: 41);

CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23  
(SEQ ID NO: 48);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42) and CJ1-20  
(SEQ ID NO: 45);

CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-20  
(SEQ ID NO: 45);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-1 (SEQ  
ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO:  
28);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22  
(SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID  
NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ  
ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47)  
and CJ1-23 (SEQ ID NO: 48);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ  
ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31 (SEQ ID NO: 56)  
and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-22 (SEQ  
ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56)  
and CJ1-32 (SEQ ID NO: 57);

215  
concl

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57); and  
CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48).

---

74. (Amended) All or a portion of an isolated peptide of Cry j I, said peptide or portion thereof comprising at least one T cell epitope of Cry j I, said peptide having an amino acid sequence selected from the group consisting of amino acid residues 1-40 (SEQ ID NO: 66), amino acid residues 81-110 (SEQ ID NO: 67), amino acid residues 151-180 (SEQ ID NO: 68), amino acid residues 191-240 (SEQ ID NO: 69) and amino acid residues 291-330 (SEQ ID NO: 70) of Cry j I as shown in Fig. 4a-b.

---

216

Please also substitute pages 53-85 which contain the Sequence Listing and renumber the claims and abstract which originally appeared at pages 66-79 as pages 86-99.

---

210  
conf

(SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-28 (SEQ ID NO: 53), CJ1-29 (SEQ ID NO: 54), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), CJ1-33 (SEQ ID NO: 58), CJ1-34 (SEQ ID NO: 59) and CJ1-35 (SEQ ID NO: 60)--;

---

In the Claims

Please amend claims 1, 18-19, 25-27, 32, 51-52 and 74 as follows:

---

211

1. (Amended) An isolated peptide of Cry j I or an isolated portion thereof comprising at least one T cell epitope of Cry j I, said peptide having an amino acid sequence selected from the group consisting of CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), and CJ1-35 (SEQ ID NO: 60).

---

18. (Amended) A peptide or portion thereof of claim 14 wherein said peptide is selected from the group consisting of: CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-35 (SEQ ID NO: 60).

19. (Amended) A peptide or portion thereof of claim 17 wherein said peptide has an amino acid sequence selected from the group consisting of: CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47), CJ1-27 (SEQ ID NO: 52) and CJ1-32 (SEQ ID NO: 57).

25. (Amended) An isolated peptide comprising at least two regions, each region comprising at least one T cell epitope of Cry j I, said regions each comprising all or a portion of an amino acid sequence selected from the group consisting of: CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17

(SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-28 (SEQ ID NO: 53), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), CJ1-33 (SEQ ID NO: 58), CJ1-34 (SEQ ID NO: 59) and CJ1-35 (SEQ ID NO: 60).

26. (Amended) All or a portion of an isolated peptide of claim 25 wherein said regions comprise an amino acid sequence selected from the group consisting of: CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-35 (SEQ ID NO: 60).

27. (Amended) An isolated peptide of claim 25, wherein said peptide comprises a combination of regions selected from the group consisting of:

CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-1 (SEQ ID NO: 26) and CJ1-2 (SEQ ID NO: 27);

CJ1-9 (SEQ ID NO: 34) and CJ1-10 (SEQ ID NO: 35);

213  
CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16  
(SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);  
CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22  
(SEQ ID NO: 47), CJ2-23 (SEQ ID NO: 48);  
CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47) and CJ1-23  
(SEQ ID NO: 48);  
CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);  
CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48) and CJ1-24  
(SEQ ID NO: 49);  
CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56) and CJ1-32  
(SEQ ID NO: 57);  
CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);  
CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-16  
(SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42):  
CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31  
(SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);  
CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31  
(SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);  
CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35) and CJ1-16  
(SEQ ID NO: 41);  
CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23  
(SEQ ID NO: 48);  
CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42) and CJ1-20  
(SEQ ID NO: 45);

CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-20 (SEQ ID NO: 45);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57); and

CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48).

---

32. (Amended) All or a portion of an isolated peptide of Cry j I, said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide having the formula  $X_n$ -Y- $Z_m$ , wherein Y is an amino acid sequence selected from the group consisting of: CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), and CJ1-35 (SEQ ID NO: 60) wherein  $X_n$  are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of said protein allergen, wherein  $Z_m$  are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of said protein allergen, wherein n is 0-30 and wherein m is 0-30.



215

51. (Amended) A composition of claim 50 wherein said peptides are selected from the group consisting of: CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-3 (SEQ ID NO: 28), CJ1-4 (SEQ ID NO: 29), CJ1-7 (SEQ ID NO: 32), CJ1-8 (SEQ ID NO: 33), CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-11 (SEQ ID NO: 36), CJ1-12 (SEQ ID NO: 37), CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-18 (SEQ ID NO: 43), CJ1-19 (SEQ ID NO: 44), CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-24 (SEQ ID NO: 49), CJ1-25 (SEQ ID NO: 50), CJ1-26 (SEQ ID NO: 51), CJ1-27 (SEQ ID NO: 52), CJ1-28 (SEQ ID NO: 53), CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57), CJ1-33 (SEQ ID NO: 58), CJ1-34 (SEQ ID NO: 59) and CJ1-35 (SEQ ID NO: 60) and wherein said composition comprises a sufficient percentage of the T cell epitopes of said protein allergen such that upon administration of the composition to an individual sensitive to a Japanese cedar pollen allergen, T cells of the individual are tolerized to said at least one protein allergen.

-

52. (Amended) A composition of claim 51 comprising a combination of peptides selected from the group consisting of:

CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-1 (SEQ ID NO: 26) and CJ1-2 (SEQ ID NO: 27);

CJ1-9 (SEQ ID NO: 34) and CJ1-10 (SEQ ID NO: 35);

CJ1-14 (SEQ ID NO: 39), CJ1-15 (SEQ ID NO: 40), CJ1-16 (SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);

CJ1-20 (SEQ ID NO: 45), CJ1-21 (SEQ ID NO: 46), CJ1-22 (SEQ ID NO: 47), CJ2-23 (SEQ ID NO: 48);

CJ1-20 (SEQ ID NO: 45), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48) and CJ1-24 (SEQ ID NO: 49);

CJ1-30 (SEQ ID NO: 55), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-16 (SEQ ID NO: 41) and CJ1-17 (SEQ ID NO: 42);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

2/5  
CJ1-23

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35) and CJ1-16 (SEQ ID NO: 41);

CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42) and CJ1-20 (SEQ ID NO: 45);

CJ1-31 (SEQ ID NO: 56), CJ1-32 (SEQ ID NO: 57) and CJ1-20 (SEQ ID NO: 45);

CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27) and CJ1-3 (SEQ ID NO: 28);

CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57);

215  
2024

215  
concl

CJ1-9 (SEQ ID NO: 34), CJ1-10 (SEQ ID NO: 35), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47), CJ1-23 (SEQ ID NO: 48), CJ1-31 (SEQ ID NO: 56) and CJ1-32 (SEQ ID NO: 57); and CJ1-1 (SEQ ID NO: 26), CJ1-2 (SEQ ID NO: 27), CJ1-16 (SEQ ID NO: 41), CJ1-17 (SEQ ID NO: 42), CJ1-22 (SEQ ID NO: 47) and CJ1-23 (SEQ ID NO: 48).

---

216

74. (Amended) All or a portion of an isolated peptide of Cry j I, said peptide or portion thereof comprising at least one T cell epitope of Cry j I, said peptide having an amino acid sequence selected from the group consisting of amino acid residues 1-40 (SEQ ID NO: 66), amino acid residues 81-110 (SEQ ID NO: 67), amino acid residues 151-180 (SEQ ID NO: 68), amino acid residues 191-240 (SEQ ID NO: 69) and amino acid residues 291-330 (SEQ ID NO: 70) of Cry j I as shown in Fig. 4a-b.

---

Please also substitute pages 53-85 which contain the Sequence Listing and renumber the claims and abstract which originally appeared at pages 66-79 as pages 86-99.